HighTower Advisors LLC Has $1.48 Million Stake in Bio-Rad Laboratories, Inc. $BIO

HighTower Advisors LLC trimmed its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 2.7% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,079 shares of the medical research company’s stock after selling 171 shares during the period. HighTower Advisors LLC’s holdings in Bio-Rad Laboratories were worth $1,480,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. Lecap Asset Management Ltd. grew its stake in Bio-Rad Laboratories by 3.1% during the first quarter. Lecap Asset Management Ltd. now owns 1,600 shares of the medical research company’s stock worth $390,000 after buying an additional 48 shares in the last quarter. State of Alaska Department of Revenue grew its stake in Bio-Rad Laboratories by 2.5% during the first quarter. State of Alaska Department of Revenue now owns 2,254 shares of the medical research company’s stock worth $548,000 after buying an additional 55 shares in the last quarter. ProShare Advisors LLC grew its stake in Bio-Rad Laboratories by 8.0% during the fourth quarter. ProShare Advisors LLC now owns 901 shares of the medical research company’s stock worth $296,000 after buying an additional 67 shares in the last quarter. GeoWealth Management LLC grew its stake in Bio-Rad Laboratories by 342.9% during the fourth quarter. GeoWealth Management LLC now owns 93 shares of the medical research company’s stock worth $31,000 after buying an additional 72 shares in the last quarter. Finally, Park Avenue Securities LLC grew its stake in Bio-Rad Laboratories by 4.4% during the first quarter. Park Avenue Securities LLC now owns 2,391 shares of the medical research company’s stock worth $582,000 after buying an additional 100 shares in the last quarter. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on BIO shares. Wall Street Zen lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Friday. Citigroup lowered their price objective on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Royal Bank Of Canada upped their price objective on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an “outperform” rating in a research report on Friday, August 1st. Wells Fargo & Company upped their price objective on shares of Bio-Rad Laboratories from $245.00 to $265.00 and gave the stock an “equal weight” rating in a research report on Friday, August 1st. Finally, UBS Group lowered their price objective on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $333.50.

Bio-Rad Laboratories Stock Up 6.3%

Shares of NYSE BIO opened at $302.99 on Monday. The company has a 50 day simple moving average of $257.27 and a 200 day simple moving average of $251.99. The firm has a market cap of $8.20 billion, a PE ratio of 25.83 and a beta of 0.90. Bio-Rad Laboratories, Inc. has a 1 year low of $211.43 and a 1 year high of $387.99. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.12 and a quick ratio of 3.67.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Thursday, July 31st. The medical research company reported $2.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.93 by $0.68. The business had revenue of $651.60 million during the quarter, compared to analyst estimates of $614.82 million. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.01%. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the business earned $3.11 EPS. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. On average, research analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.